Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

New approaches to drug safety: a pharmacovigilance tool kit

Nature Reviews Drug Discovery volume 8, pages 779–782 (2009)Cite this article

Abstract

The importance of pharmacovigilance — the ongoing assessment of the safety of a marketed medicine — has been increasingly appreciated in recent years, owing in part to high-profile safety issues with widely used drugs. In response, strategies to improve the collection, integration and analysis of data related to post-marketing drug safety are being initiated or enhanced. In this article, we summarize the key tools that are available for pharmacovigilance, discuss which might be the most appropriate to use in different situations and consider the future directions of the field.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Evans, S. in Pharmacovigilance 2nd edn Ch. 19 (eds Mann, R. & Andrews, E.) 249–255 (John Wiley, Chichester, 2007).

    Google Scholar 

  2. Medicines and Healthcare products Regulatory Agency. Drug Safety Update: Volume 1, Issue 12 [online] (2008).

  3. Ransohoff, R. M. et al. Natalizumab for multiple sclerosis. N. Engl. J. Med. 356, 2622–2629 (2007).

    Article  CAS  Google Scholar 

  4. Silman, A., Symmonds, D., Scott, D. G. I. & Griffiths, I. British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 62, S28 (2003).

    Article  Google Scholar 

  5. Morrow, J. et al. Malformation risks of antiepileptiform drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatr. 77, 193–198 (2006).

    Article  CAS  Google Scholar 

  6. del Toro-Riera, M. et al. Follow up of patients with Hunter syndrome: the Hunter Outcome Survey (HOS) registry. Rev. Neurol. 44, S513–S517 (2007).

    Google Scholar 

  7. Biederbeck-Noll, A. B. et al. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur. J. Cancer. 39, 98–105 (2003).

    Article  Google Scholar 

  8. Harrison-Woolrych, M. et al. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Safety 7, 569–573 (2007).

    Article  Google Scholar 

  9. Lesko, S. M. and Mitchell, A. A. The safety of acetaminophen and ibuprofen among children younger than two years old. Paediatrics 104, 39–51 (1999).

    Article  Google Scholar 

  10. Friis-Moller, N. et al. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993–2003 (2003).

    Article  Google Scholar 

  11. Segal, E. S. et al. Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Safety 28, 971–980 (2005).

    Article  Google Scholar 

  12. Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568–570 (2008).

    Article  Google Scholar 

  13. Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M. Current assessment of risk–benefit by regulators: is it time to introduce decision analyses? Clin. Pharmacol. Ther. 82, 123–127 (2007).

    Article  CAS  Google Scholar 

  14. van Staa. T. P., Smeeth, L., Persson, I., Parkinson, J. & Leufkens, H. G. What is the harm–benefit ratio of Cox-2 inhibitors? Int. J. Epidemiol. 37, 405–413 (2008).

    Article  CAS  Google Scholar 

  15. van Staa, T. P., Barlow, D., Cooper, C. & Leufkens, H. G. M. Individualising risks and benefits of hormone therapy. Menopause 15, 374–381 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lesley Wise, John Parkinson, June Raine and Alasdair Breckenridge are at the Medicines and Healthcare products Regulatory Agency, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK.,

    Lesley Wise, John Parkinson, June Raine & Alasdair Breckenridge

Authors
  1. Lesley Wise
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Parkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. June Raine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alasdair Breckenridge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alasdair Breckenridge.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wise, L., Parkinson, J., Raine, J. et al. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev Drug Discov 8, 779–782 (2009). https://doi.org/10.1038/nrd3002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3002

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing